Linares-Segovia B, Rodríguez-Osorio JA, Storms-Salas G, Cervantes-Villarreal E

Language: Spanish
References: 12
Page: 51-54
PDF size: 133.13 Kb.

ABSTRACT

Objective: to compare in postmenopausal women with osteoporosis or osteopenia the effect of hydrochlorate of raloxifene versus hormone replacement therapy on the mammary density.
Method: a double blind, randomized clinical trial was conducted in 57 postmenopausal women older than 55 years with osteoporosis or osteopenia. Participants were randomly allocated in two groups: the intervention group (IG) received hydrochlorate of raloxifene and the control group (CG) received hormone replacement therapy during 6 months. A mammography to evaluate the change of the mammary density, according to the BIRADS criteria, was made before and after the treatment.
Results: twenty-eight patients received hormone replacement therapy and 29 hydrochlorate of raloxifene. Eight (28.5%) patients of the IG and one (3.0%) of the CG showed an increased mammary density; whereas in none of IG patients and in four (13.7%) of the CG, the mammary density decreased (p = 0.01).
Conclusions: the hydrochlorate of raloxifene in postmenopausal women with osteoporosis or osteopenia does not increase the mammary density.

REFERENCES

1. Norma Oficial Mexicana NOM-035-SSA2-2002, Prevención y control en la perimenopausia y posmenopausia de la mujer. Criterios para brindar la atención médica. México: Diario oficial de la Federación 18 de septiembre del 2003.

2. American College of Radiology (ACR). Illustrated Breast Imaging Reporting and Data System (BIRADS). 3rd ed. Reston, USA: American College of Radiology; 1998.

3. Lundstrom E, Wilczek B, Von-Palffy Z, Soderqvist G, Von-Schoultz B. Mammographic breast cancer density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens. Climacteric 2001;4:42-48.

4. Dupont W, Page D. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67-72.

5. Freedman M, Martin JS, O’ Gorman J, Rckert S, Lippman ME, Lo SC, et al. Digitized mammography: a clinical trial of post-menopausal women randomly assigned to receive raloxifeno, estrogen, or placebo. J Natl Cancer Inst 2001;93:51-56.

6. Cummings SR, Eckert S, Krueger K, Grady D, Powles TJ, Cauley J, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 1999;281:2189-2197.

7. Ortiz-Núñez DA, Mengchún-López G, Hernández- Marín I, Mendoza R, Ayala-Ruiz AR. Ausencia de efecto antiosteopénico de la terapia hormonal de reemplazo en mujeres posmenopáusicas. Ginecol Obstet Mex 2004;72:349-355.

8. Greendale GA, Reboussin BA, Sie A, Sinqh HR, Olson LK, Gatewood O, et al. Effects of estrogen and estrogen–progestin on mammographic parenchymal density. Ann Intern Med 1999;130: 262-269.

9. Wakeling AE, Valcaccia B, Newboult E, Green LR. Non-steroidal antiestrogens: receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem 1984; 20:111-120.

10. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea- induced rat mammary carcinoma model. Cancer Res 1987;47:4020-4024.

11. Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 1996;88:123-125.

12. Jordan VC, Glusman JE, Eckert S, Lippman M, Powles T, Costa A, et al. Raloxifene reduces incident primary breast cancer: integrated data from multicenter, double-blind, placebo-controlled, randomized trials in postmenopausal women. 21st Annual San Antonio Breast Cancer Symposium. Abstracts. Breast Can Res Treat 1998;50:227.